Calcium Balance Drugs

Front 1

Teripartide- Class, Use, MOA, PK, CI

Back 1

Class: recombinant PTH
Use: osteoporosis
MOA: increases calcium absorption to bones
PK: low dose only, at high doses will cause bone loss b/c will cause increased release of calcium from bone
CI: hypersensitivity

Front 2

Cholecalciferol, ergocalciferol- Class, MOA

Back 2

Class: liver activated analog, liver will covert D3 adn D2 into 25(OH) D and store them, then the kidney will further activate (PTH controls this process)

Front 3

Calcitriol- Class, Use, MOA

Back 3

Class: vit D activated or liver activated analog
Use: hypocalcemia due to renal deficiency, 2ndary hyperparathyroidism
MOA: bypasses kidney activation, inhibits PTH secretion

Front 4

Calcitriol, doxecalciferol-Tox

Back 4

Tox: hypercalcemia, hyperphosphatemia, hypercalciuria

Front 5

Paricalcitol- Class, Use, MOA, Tox

Back 5

Class: VIt D activated or liver activated analog
Use: 2ndary hyperparathyroidism
MOA: bypasses kidney activation and inhibits PTH secretion
Tox: less vitamin D toxicity

Front 6

Cinacalcet- Class, Use, MOA, Tox

Back 6

Class: calcimimetics
Use: 2ndary hyperparathyroidism
MOA: increases sensitivity of the calcium sensing receptor to free Ca+ which in tunr lowers PTH output
Tox: sz, hypocalcemia

Front 7

Calcitonin- Use, MOA

Back 7

Use: Pagets Dz, hypercalcemia, osteoporosis
MOA: antagonizes PTH, acts at the calcitonin receptor to inhibit calcium intake into the gut and inhibits calcium release from bones, adn inhibit calcium and phosphate reabsorption by the kdiney

Front 8

Prednisone- Class, Use, MOA

Back 8

Class: glucocorticoids
Use: cancer associated hypercalcemia
MOA: antagonizes Vit D

Front 9

Alendronate, pamidronate, risedronate- Class, Use, MOA, Tox

Back 9

Class: bisphosphonates
Use: cancer associated hypercalcemia, osteoporosis, Pagets dz
MOA: inhibits osteoclasts,
Tox: erosive esophagitis, osteonecrosis of the jaw

Front 10

Raloxifene- Class, Use, MOA, Tox/CI

Back 10

Class: selective estrogen receptor modulators
Use: postmenopausal osteoporosis
MOA: agonist in bones, antagonist in uterus and breasts
Tox: hot flashes
CI: lactating or pregnant women or women w/ hx of thromboembolism

Front 11

Gallium nitrate-MOA

Back 11

inhibits osteoclasts

Front 12

Plicamycin- MOA

Back 12

inhibits osteoclasts

Front 13

Furosemide-MOA

Back 13

increases calcium excretion

Front 14

Thiazides-MOA

Back 14

decrease calcium excretion

Front 15

Sevelamer- Use, MOA

Back 15

Use: if pt has hyperphosphatemia
MOA: sequesters phosphate in food so cannot be absorbed

Front 16

PTH increases calcium and phosphate intake in the ___
PTH decreases __ excretion and increases ___ excretion in the kidney.
PTh ___ calcium and phosphate release from bones

Back 16

1. gut
2. calcium excretion is decreased
3. phosphate excretion is increased
4. increases

Front 17

The PTH receptor is a ___ coupled membrane receptor and acts on the gut through ___

Back 17

1. G protein coupled membrane
2. vitamin D

Front 18

High levels of calcium will inhibit the secretion of ___ via calcium sensing receptors which are ___ in the parathyroid gland.

Back 18

1. PTH
2. G protein coupled receptors

Front 19

PTHs effect in the gut of increasing calcium absorption is mediated via ____. PTH stimulates the kidney portion of the activation of 1.
1. then allows increased calcium transport in the ___

Back 19

1. vitamin D
2. gut

Front 20

Activated vitamin D ___ PTH secretion and ___ the activation of more Vitamin D.
KIDNEYS are ESSENTIAL for operation of vitamin D loops

Back 20

1. inhibits
2. inhibits

Front 21

Estrogens- __ calcium release from bones thus estrogen replacement will help post menopausal women

Back 21

1. decrease

Front 22

Doxercalciferol- MOA

Back 22

- similar to calcitriol, prodrug which is activated in the liver